Copyright
©2013 Baishideng Publishing Group Co.
World J Ophthalmol. Aug 12, 2013; 3(3): 20-31
Published online Aug 12, 2013. doi: 10.5318/wjo.v3.i3.20
Published online Aug 12, 2013. doi: 10.5318/wjo.v3.i3.20
Stage | Characteristics |
Stage I | Eccentric bulging |
Induced myopia and/or astigmatism of 5 D | |
Average central keratometry of 48 D | |
Stage II | Induced myopia and/or astigmatism of 5 to 8 D |
Average central keratometry > 48 D but < 53 D | |
Absent scarring | |
Minimum corneal thickness of 400 microns | |
Stage III | Induced myopia and/or astigmatism of 8 to 10 D |
Average central keratometry > 53 D | |
Absent scarring | |
Central corneal thickness of 300 to 400 microns | |
Stage IV | Invaluable refraction |
Average central keratometry > 55 D | |
Central corneal scar | |
Corneal thickness < 200 microns |
- Citation: Jaimes M, Ramirez-Miranda A, Graue-Hernández EO, Navas A. Keratoconus therapeutics advances. World J Ophthalmol 2013; 3(3): 20-31
- URL: https://www.wjgnet.com/2218-6239/full/v3/i3/20.htm
- DOI: https://dx.doi.org/10.5318/wjo.v3.i3.20